You are here
P&T May 2011
Determining the mutation status of two genes, EGFR and KRAS, may enable health care professionals to identify which patients with non–small-cell lung cancer are likely to benefit from anti-epidermal growth factor receptor–tyrosine kinase inhibitor therapy rather than from chemotherapy.
An Economic Stimulus Plan for Missouri
46th European Association for the Study of the Liver